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Abstract
Introduction: Muscle atrophy results from a dysfunction in protein turnover that leads to loss of
mass and function and occurs concurrently with multiple pathologies such as cancer and
extended bed rest. Atrophy reduces overall quality of life while increasing morbidity and
mortality. Currently, efficacious therapeutic interventions to treat and prevent muscle wasting in
all its forms are lacking, however if conserved mechanisms can be identified between wasting
conditions, this would aid in the development of multipurpose therapeutics to ameliorate this
pathology. Purpose: To examine circulating factors present across atrophic pathologies.
Methods: 35 Male C57BL/6J mice were assigned to hindlimb unloading (HU), Lewis Lung
Carcinoma (LLC), or control groups. HU animals were hindlimb-unloaded for 1 week to induce
disuse atrophy. LLC cells were injected into the right hind-flank to induce cancer cachexia.
Tumors developed for approximately 4 weeks. Age-matched mice were humanely euthanized
after experimental intervention. Muscle and plasma were collected for analysis. Plasma was
analyzed by tandem mass tag (TMT) proteomics. Results: Raw plantaris weight was
significantly lower in LLC (22.7%) and HU (18.6%) groups compared to control (p<0.05), but
not different from each other (p>0.05). Equivalent tibia sizes across groups suggest no
significant differences in body size. In the LLC-HU comparison, 104 proteins were differentially
expressed (DE). 44 were up-regulated and 60 were down-regulated. In the LLC-CON
comparison, 91 DE proteins were observed. Of these, 39 were up-regulated and 52 were downregulated. In the HU-CON comparison, 5 DE proteins were up-regulated and 4 were downregulated; a total of 9 DE proteins were observed. Several signaling pathways were implicated in
this analysis including the acute phase response signaling system and liver X receptor/retinoid X
receptor (LXR/RXR) and farnesoid X receptor/retinoid X receptor (FXR/RXR) activation.

Conclusion: Plasma proteomic profiles are altered in cancer cachexia and disuse-induced
atrophy. Modulated protein profiles suggest the possibility of multi-tissue involvement in muscle
atrophy. Future experiments are required to understand how plasma proteins and muscle interact
and to determine the mechanisms of possible novel atrokines observed herein.
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Chapter 1: Literature Review
Muscle Atrophy Overview
Muscle atrophy is a pathological dysfunction in protein turnover where an imbalance in
protein synthesis and degradation leads to an overall loss in muscle mass and muscle function
(32). Atrophy is a serious condition that is often experienced as a side effect of many other
diseases including cancer, AIDS, sepsis, muscular dystrophies and chronic inflammatory
diseases, and states of disuse such as casting, forced bed rest, or space flight. Unfortunately,
atrophy is also exacerbated by drugs intended to treat some of those same diseases, including
common chemotherapeutics such as dexamethasone (26, 47). Atrophy, also commonly referred
to as muscle wasting, increases morbidity and mortality in these patients while significantly
reducing quality of life (45). Currently, safe and efficacious therapeutic interventions to treat and
prevent muscle wasting are lacking. Therefore, the objective of this review will be to examine
the different forms of muscle wasting and what factors influence the mechanism of these various
etiologies.
Types of Muscle Wasting
Muscle atrophy stems from several etiologies including cancer cachexia, disuse,
denervation, dystrophy, sarcopenia, and sepsis. However, skeletal muscle does not respond to
these conditions in the same manner. Cancer cachexia occurs secondary to tumors. Patients with
gastric and pancreatic cancers are particularly vulnerable to developing cachexia (21). These
conditions elevate the immune response in the body, creating an inflammatory environment.
Cancer cachexia primarily affects type II fibers (11). In contrast to cachexia, muscle unloading
via forced bed rest, casting, and space flight does not lead to inflammation. In this environment,
type I fibers are more susceptible to wasting (15). Denervation is an atrophy model that
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recapitulates spinal cord injury. The wasting that occurs secondary to denervation is similar to
disuse. Inflammation is not induced, and type I fibers are primarily afflicted (15). Duchenne’s
muscular dystrophy is a genetic disorder that disrupts the linkage of the muscle cell’s contractile
apparatus to the extracellular matrix (15, 30). This disorder causes severe muscle damage,
inflammation, and premature death (16). Fiber types are not discriminated in muscular
dystrophy. Sarcopenia is an age-related condition that leads to the loss of muscle mass (18). In
this condition, inflammation is elevated and, similar to cancer cachexia, type II fibers are the
primary target of wasting (35). Sepsis is a life-threatening organ dysfunction secondary to a
dysregulated host response to an infection (56). In order to protect itself from the infection, the
body dramatically elevates its inflammatory response (51). While this is necessary for survival, it
is detrimental to skeletal muscle tissue, particularly type II fibers (66). Atrophy occurs under
many circumstances and the skeletal muscle exhibits divergent responses to these stimuli.
Therefore, the remainder of this review will focus on comparing cancer cachexia and disuseinduced atrophy.
Cancer Cachexia
Cancer cachexia is characterized by a significant loss in body weight due to decreases in
muscle mass, with or without fat loss. Cachexia is currently responsible for approximately 20%40% of cancer deaths (22). Patients with gastric or pancreatic cancers are especially prone to
cachexia (23). It was originally thought that decreased nutritional intake was largely responsible
for the development of cachexia. However, current evidence suggests that resolving hypophagia
is not sufficient to prevent and reverse cachexia (29). This is an extremely complex metabolic
disorder in which protein anabolism, protein catabolism, and energy metabolism are all affected.
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Protein Anabolism
Significant evidence suggests that protein anabolism is reduced in cachexia (7, 11, 57, 59,
61, 69). For example, Smith and Tisdale (57) utilized a MAC16 adenocarcinoma injectable
cancer model to examine the effect of cancer on protein turnover. The authors implanted mice
with a tumorigenic strain of cells. After 10-12 days of implantation, the authors observed
palpable tumors. Animals were sacrificed and gastrocnemii were harvested for protein turnover
analysis using radioactive labeling techniques. They observed that a body weight loss of 15%30% corresponded to a 60% decrease in protein synthesis. Similarly, Samuels et al. (50) utilized
a C26 adenocarcinoma cancer model to examine the effect of cancer cachexia and chemotherapy
on protein synthesis and degradation. The authors employed the flooding dose method to
measure protein turnover in vivo. They found that after the onset of cancer cachexia, mice
exhibited significant reductions in protein synthesis. The incorporation of the chemotherapeutic
agent cystemustine rescued protein synthetic rates in tumor bearing animals. At this point, there
is a consensus that protein synthesis is down regulated in cancer cachectic subjects.
This decrease in protein synthetic rate is likely due to the down-regulation of several
anabolic factors including insulin-like growth factor 1 (IGF-1), Akt, mTOR, and satellite cells
(22, 58). IGF-1, Akt, and mTOR are connected in a prominent PI3K/Akt protein synthetic
pathway. In healthy conditions, insulin binds IGF-1 which leads to a conformational change in
the receptor and phosphorylates intracellular IRS-1. Activated IRS-1 causes a cascade of
phosphorylation events that activates Akt and leads to the activation of mTOR. Phosphorylated
mTOR is associated with a dissociation of binding protein 4E-BP1 from the eukaryotic initiation
factors 4G and 4E that form a scaffold and bind to the 5’ region of mRNA. This dissociation
allows for the binding of 4A and the formation of the 4F complex that allows for ribosomal
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recruitment and mRNA translation (55). A down-regulation of any of these factors will
negatively influence protein synthesis. Satellite cells are unipotent stem cells necessary for
muscle maintenance, repair, and hypertrophy (20). When signaled by damage, satellite cells
proliferate, differentiate, and migrate to the site they are required. A decrease in the available
pool of satellite cells limits muscle growth and repair. A perturbation in any of these anabolic
factors will limit or reduce overall protein synthetic rates in afflicted muscle.
Protein Catabolism
The available literature suggests that protein catabolism is elevated in cancer cachexia
(11, 60, 62, 69,72). Smith and Tisdale (57) observed a significant increase in protein degradation
with a 16%-20% weight loss. They measured protein degradation in situ in the gastrocnemius via
radioactive labeling techniques. They reported a maximal increase of catabolism at 240% from
healthy conditions when weight loss was at 30%. Additionally, Samuels et al. (50) observed
significant increases in protein degradation at the onset of cachexia. Their chemotherapeutic
agent did not increase this effect. It is worth noting that they measured degradation indirectly by
extrapolating the relationship between growth and synthesis. Studying protein degradation is
difficult, but there seems to be a consensus that catabolism is significantly elevated under
cachectic conditions (32).
This elevation in degradation may be due to the up-regulation of several catabolic
markers including cytokines, myostatin, forkhead box O (FoxO), reactive oxygen species (ROS),
nuclear factor (NF-ĸB), and proteolysis inducing factor (PIF) (22, 58). NF-ĸB is one of the
primary transcription factors that transduces (tumor necrotic factor) TNF-α signals into cells.
NF-ĸB is also responsible for activating the gene expression of other cytokines. Together, tumor
factors and cytokines up-regulate the ubiquitin-proteasome system, promoting protein
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degradation. FoxO transcription factors also play a major role in catabolism. In healthy
conditions, FoxO is phosphorylated by PI3K/Akt and is inactivated. In its active conformation,
FoxO translocates to the nucleus and up-regulates the expression of skeletal muscle specific E3
ubiquitin ligases muscle RING-finger protein-1 (MuRF1) and atrogin-1/muscle atrophy F-box
(MAFbx). FoxO also up-regulates the expression of other autophagy related genes LC3 and
Bnip3. The FoxO system is influenced by ROS, PIF, and IGF-1, all of which are modulated by
cachexia. PIF plays an additional role in catabolism as it is shown to inhibit mRNA translation
via phosphorylation of the eukaryotic initiation factor 2α. Myostatin also contributes to
cachexia’s catabolic effect. Myostatin is a well-known protein responsible for negatively
regulating muscle mass. In healthy conditions, myostatin expression is regulated by IGF-1.
However, due to the down-regulation of IGF-1 in cachexia, myostatin can be overexpressed,
attenuating muscle growth and contributing to a loss in muscle mass (58). Several pathways are
involved in protein catabolism. The pathologic modulation of these pathways contributes to an
undesired up-regulation of protein degradation.
Energy Metabolism
Mitochondria are crucial for energy metabolism in skeletal muscle. However, it is not
enough to consider mitochondria as the ‘powerhouse of the cell” without also considering
mitochondrial quality which relates to the overall health and function of the mitochondrial
network. An impaired mitochondrial network produces less ATP and significantly more reactive
oxygen species (ROS) which is detrimental to cell health (1). The mitochondria regulate network
quality through various processes. These include the biogenesis of new mitochondrial materials,
the incorporation of new material and removal of dysfunctional mitochondria via fusion and
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fission (dynamics), and the autophagic removal of mitochondria that have been removed from
the network (mitophagy) (49, 73).
Evidence suggests that the mitochondrial network is impaired in cancer cachexia and may
play an initiating role (10, 33, 43, 44, 64). Brown et al. (10) utilized the ApcMin/+ genetic model
for colorectal cancer and a Lewis Lung Cancer (LLC) injectable cancer model to understand the
cellular events that occur in the development of cancer cachexia. A cachectic phenotype was
observed 4 weeks post-injection in the LLC animals. However, mitochondrial respiration was
significantly decreased at 3 weeks and ROS production was significantly increased at 1 week.
We electroporated the right flexor digitorum brevis with the fluorescent reporter gene
pMitoTimer to observe mitochondrial quality via fluorescence microscopy (36). In the presence
of this reporter protein, healthy mitochondria fluoresce green while unhealthy mitochondria
oxidize the protein and fluoresce red. This allows the red:green ratio in these images to be
analyzed to determine mitochondrial quality. At 2 weeks, mitochondrial quality was
compromised in these animals. Marzetti et al. (38) performed a study in human cancer cachectic
patients and observed perturbations in gene expression related to the regulation of mitochondrial
quality. The authors performed muscle biopsies on the rectus abdominus of their subjects
(control, cancer, cancer cachexia groups). They observed that fusion protein Mfn2 was downregulated in both cancer groups regardless of cachexia diagnosis. However, they found that the
fission protein Fis1 was significantly up-regulated only in the cachexia cohort. They did not note
any significant differences in the expression of the master regulator of biogenesis, PGC-1α.
Interestingly, mitophagy proteins PINK1 and Parkin were significantly down-regulated in both
cancer conditions which may suggest impaired or failed mitophagy. Remarkably, the
upregulation of Fis 1 corresponds to observations made by Brown et al. (10) in LLC cachectic
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mice. Regardless of species, there is evidence that degeneration of mitochondria is involved in
the pathogenesis of cancer cachexia.
Disuse-Induced Atrophy
Disuse-induced atrophy is common in forced bed-rest, limb casting, and space flight (4).
In these conditions, atrophy is associated with the lack of muscular tension, or unloading.
Whether temporary or prolonged, this disuse can have deleterious effects on force production
and increase mortality and morbidity. There are currently no interventions, pharmaceutical or
otherwise, available to treat or prevent this disorder. While disuse atrophy is not associated with
the inflammation commonly observed in cachexia, protein anabolism, protein catabolism, and
energy metabolism are all affected (48).
Protein Anabolism
The literature suggests that protein synthetic rates are blunted by disuse-induced atrophy
(34, 48, 54). Kazi et al. (34) examined disuse atrophy in hindlimb suspended C57BL/6J mice.
The gastrocnemii were harvested and flooding dose methodology was used to determine protein
synthesis following 3 days of suspension. At this time point, muscles had wasted and protein
synthesis was significantly decreased. According to their data from DEPTOR knockdown
animals, it appears that this decrease in anabolism is likely due to mTOR mediated synthesis
inhibition. Similarly, Baehr et al. (5) examined the muscle-specific and age-related changes in
protein synthesis and degradation in response to hindlimb suspension in rats. The authors were
also able to detect wasting in the gastrocnemius after 3 days of suspension. Protein synthesis was
assessed using the SuNSET method. Anabolism was decreased in all hindlimb muscles at 3 and 7
days. The synthetic rate in the soleus remained low at 14 days. These data suggest a fiber type
dependent response to protein anabolism.
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The mTOR pathway is a critical regulatory system for protein anabolism which is
negatively impacted by disuse (4, 54). Specifically, Kazi et al. (34) suggest that knocking down
DEPTOR, an mTOR inhibitor, can rescue protein synthesis in hindlimb unloading. It is known
that acute immobilization can alter the expression of more than 600 mRNAs, but their exact
effects remain essentially unexplored. Promising targets have emerged from this data. Two
transcription factors, activating transcription factor 4 (ATF4), and p53 are up-regulated in
atrophy. These proteins are shown to be sufficient in the generation of atrophy. Additionally,
p21, an inhibitor of cyclin-dependent kinases is up-regulated in immobilization induced atrophy.
Downstream from p21 is spermine oxidase. It appears that the up-regulation of p21 leads to the
inhibition of spermine oxidase and, in turn, atrophy (4). These discoveries are potentially
impactful in developing treatments for atrophy. However, more work is needed to determine the
mechanism through which these proteins act on skeletal muscle in wasting conditions. Though
the data do not completely agree, it seems that protein synthesis is blunted to a degree in most
tissues upon unloading.
Protein Catabolism
Baehr et al. (5) examined both protein synthesis and degradation. They indirectly
observed catabolism by analyzing the activities of catabolic markers proteasome and cathepsin
L. They suggest that catabolism was increased in the soleus and tibialis anterior muscles of adult
rats. They did not observe any changes in catabolic markers in older animals. This suggests an
age and fiber type-modulated response to hindlimb unloading. Overall, protein metabolism is
affected in unloaded animals. The degree to which anabolism and/or catabolism contributes
appears to depend on several factors including age, fiber type, and duration of unloading.
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mRNA evidence suggests an up-regulation of the catabolic factors MuRF1, MAFbx,
FoxO, and FoxO3a in unloading-induced atrophy (4). Insulin resistance will attenuate the
PI3K/Akt pathway, leaving FoxO in its active conformation. As previously described (22, 58),
FoxO will translocate to the nucleus and up-regulate the transcription of E3 ubiquitin ligases
MuRF1 and MAFbx. However, it is suggested that the expression of these markers is dependent
on the muscle being studied and its time spent unloaded. More work is needed to elucidate the
importance of these potential metabolic pathways.
Energy Metabolism
As previously discussed, proper mitochondrial function is imperative to cellular health
(46). Cannavino et al. (14) examined the influence of PGC-1α overexpression on hindlimb
unloaded mice. They used C57BL/6J and transgenic mice that overexpressed the mitochondrial
biogenesis protein PGC-1α in the skeletal muscle. These animals were suspended for 3, 7, and 14
days. At the given time points, animals were sacrificed and gastrocnemii were harvested for
analysis. They found that fusion was impaired in WT animals that had been suspended for 3
days. A change in the oxidative capacity of the muscle suggested impaired mitochondrial
function. This dysfunction led to AMPK induced autophagy. They also found that PGC-1α
overexpression preserved muscle mass in unloaded conditions. Additionally, overexpression
prevented dysfunction of mitochondrial fusion and prevented catabolism via the AMPK
pathway. The same laboratory examined the interaction between PGC-1α, mechanical unloading,
and the soleus (13). Similar to their other findings, hindlimb unloading leads to muscle wasting.
In this model, a redox imbalance was observed after unloading. Hindlimb suspension induced
catabolic pathways and reduced protein synthetic rates. The authors tried to prevent catabolism
in WT animals by treating them with the antioxidant Trolox, a vitamin E analog. They found that
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this treatment did not play a preventative role in the induction of catabolic systems. Not
surprisingly, oxidative metabolism was impaired after unloading. The authors observed that
elevated PGC-1α expression protected soleus CSA, even after mechanical unloading had
occurred. This overexpression prevented catabolism without impacting protein synthesis.
These data suggest mitochondrial involvement in disuse-induced atrophy independent of
fiber-type. Moreover, the mitochondria represent a significant contributor to and potential
initiator of atrophy. This warrants further study of mitochondria as a potential therapeutic target
in wasting secondary to mechanical unloading.
Plasma Interactions
Plasma connects the cardiovascular system to every other system in the body. It circulates
oxygen introduced by the respiratory system, nutrients absorbed through the digestive system,
and hormone signals secreted by endocrine glands to target tissues. Because cancer cachexia is a
multi-organ syndrome that affects adipose, liver, heart, and skeletal muscle, there is potential for
cachectic muscle to be modulated via circulated factors (3, 67). In fact, evidence suggests that
the pro-inflammatory cytokine Interleukin 6 (IL-6) is up-regulated in the plasma of cancer
cachectic patients (9, 70). The value of proteomic profiles in biological fluids as a diagnostic tool
and source of potential treatment targets is beginning to be appreciated (19). Performing a global
plasma proteomic analysis in cancer cachexia would assist this effort and potentially lead to the
identification of novel secretory pro-cachectic factors. In addition, it is unclear whether plasma
proteomic analysis has been performed in disuse-induced atrophy. It is understood that the
mechanism of muscle wasting is dependent on the etiology of the wasting. As such, this analysis
would provide novel data that could improve our understanding of the mechanisms in disuseinduced atrophy and potentially provide overarching targets that link the two forms of atrophy.
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Purpose
Therefore, the purpose of this thesis will be to examine the differential expression of
circulating factors in cachectic and hindlimb suspended models utilizing proteomic
methodologies to detect significantly modulated signaling pathways. Doing so will improve our
knowledge of muscle atrophy by examining plasma proteomic profiles in pre-clinical models of
muscle wasting and elucidating how signaling pathways interact with muscle tissue in atrophic
states.
Objectives of Data Analysis
In order to further evaluate proteomic profiles in cancer cachexia and disuse-induced
atrophy, this investigation will: 1) describe phonotypes of LLC-induced Cancer Cachexia and
Hindlimb Suspended Animal, including body weight and tissue weight, 2) determine the number
and identity of significantly modified proteins in plasma for cancer cachectic cohort in
comparison to control, 3) determine the number and identity of significantly modified proteins in
plasma for hindlimb suspended cohort in comparison to control, 4) determine the number and
identity of significantly modified proteins in plasma for hindlimb suspended cohort in
comparison to cancer cachectic cohort, 5) determine top pathways impacted by identified
proteins in each experimental group, and 6) verify pathway modulation via Western Blot
analysis.
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Chapter 2: Comparative Plasma Proteomics in Muscle Atrophy
Induced by Cancer Cachexia and Hindlimb Unloading
Introduction
Muscle atrophy, commonly referred to as muscle wasting, is a pathological dysfunction
in protein turnover where an imbalance in protein synthesis and degradation leads to an overall
loss in muscle mass and muscle function (32). Atrophy manifests in response to many diseases
and disordered states. These pathologic stimuli trigger divergent responses in skeletal muscle.
Inflammation—as observed in cancer, sarcopenia, chronic inflammatory disease, and sepsis—
predisposes fast-twitch, glycolytic muscle fibers to wasting (11, 18, 21, 35, 51, 56, 66). Whereas
conditions of disuse, commonly not involving inflammation, such as denervation, forced bed
rest, casting, and space flight, primarily affect slower twitch, oxidative fibers (4, 15, 48). Patients
afflicted by atrophy experience increased rates of morbidity and mortality while their quality of
life is significantly reduced (45). Currently, safe and efficacious therapeutic interventions to treat
and prevent muscle wasting are lacking. To capture the breadth of this pathology, the present
study will compare pre-clinical models of cancer cachexia and disuse-induced atrophy.
Cancer cachexia is a multifactorial syndrome associated with an inflammatory
microenvironment and characterized by an ongoing loss of skeletal muscle mass, with or without
fat loss, that ultimately leads to impaired function (21). Cachexia is currently responsible for
approximately 20%-40% of cancer-related deaths and patients with gastric or pancreatic cancers
are especially prone to this complication (22, 23). Because this is a progressive form of wasting
that cannot be reversed via nutritional means alone, it is valuable to consider cancer cachexia as
a more complex metabolic disorder (29, 44). In fact, significant evidence suggests that protein
anabolism is reduced in cachexia due to the down-regulation of several anabolic factors

12

including IGF-1, Akt, and mTOR (7, 11, 22, 50, 57, 59, 61, 69). Compounding this issue, the upregulation of cytokines, myostatin, FoxO, NF-ĸB, and PIF, coupled with other indirect measures
of protein degradation, indicate an increased level of catabolism in cachectic muscle (2, 11, 22,
50, 57, 58, 60, 69,72). Taken together, a decrease in protein anabolism and increase in
catabolism contribute to a cachectic phenotype. Interestingly, evidence from our laboratory
suggests that energy metabolism is also disrupted in cancer cachexia and mitochondrial
dysfunction may even play an initiating role in this disease (1, 33, 40, 43, 49, 64, 73).
Specifically, we observed a decrease in respiration, an increase in ROS production, and
compromised mitochondrial network quality prior to the onset of cancer cachexia (10). Adding
credence to our findings, increased Fis1 content has been corroborated in human studies (38).
Collectively, evidence suggests many of the primary processes governing muscle mass
maintenance are perturbed in cancer cachexia, ultimately shifting the muscle towards a catabolic
state indefinitely. Fortunately, the involvement of these pathways presents many potential
opportunities for therapeutic targets.
Disuse-induced atrophy, associated with a lack of muscular tension, is a common
consequence of forced bed-rest, limb casting, and space flight (4). Whether temporary or
prolonged, disuse can have deleterious effects on force production and can increase mortality and
morbidity (4). Although disuse atrophy does not manifest in an inflammatory cellular
environment akin to cancer cachexia, dysfunctions in many of the same metabolic processes
have been detected (48). For example, decreased rates of protein synthesis have been observed in
disuse models and, from data suggesting rescued protein synthesis in DEPTOR knockdowns, this
observation is likely due to the modulation of the mTOR axis (5, 34, 48, 54). In addition, indirect
measures of catabolism suggest an increased catabolic rate, likely due to the up-regulation of

13

ubiquitin-proteasome markers MuRF1, Atrogin-1, FoxO, and FoxO3a (4, 5, 22, 58).
Interestingly, energy metabolism and mitochondrial function have also been implicated in
conditions of disuse (13, 14, 46). A reduction in oxidative capacity and decrease in
mitochondrial fusion have both been observed (4, 46). As in cancer cachexia, these multiple
dysfunctions disrupt protein balance and contribute to atrophy while also providing therapeutic
opportunities.
Proteomic profiles of biological fluids serve as valuable diagnostic tools and sources of
therapeutic targets (19). Because cancer cachexia is a multi-organ syndrome affecting multiple
organ systems including liver, adipose tissue, heart, and skeletal muscle, there is potential for
cachectic muscle to be modulated via circulating factors (3, 67). In fact, evidence suggests that
the pro-inflammatory cytokine IL-6 is up-regulated in the plasma of cachectic patients (9, 70).
More so, the development of cachexia in murine models of colorectal cancer is largely dependent
on IL-6 (6). Though cancer cachexia and disuse-induced atrophy target different muscles and
develop secondary to different stimuli, the same metabolic processes are disrupted, providing a
potential therapeutic link between the varying atrophic etiologies. To our knowledge, plasma
proteomic analysis comparing cancer cachexia and disuse-induced atrophy has not been
previously performed. Performing this global plasma proteomic analysis could lead to the
identification of novel secretory pro-atrophic factors, provide novel data improving our
understanding of the mechanisms in disuse-induced atrophy, and potentially reveal overarching
targets linking the two forms of atrophy. Therefore, the purpose of this thesis will be to examine
the differential content of circulating factors in cachectic and hindlimb suspended models of
muscle atrophy utilizing proteomic methodologies to detect significantly modulated signaling
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pathways. Doing so will improve our knowledge of muscle atrophy by elucidating how signaling
pathways interact with muscle tissue in atrophic states.
Methods
Animals and Interventions
All animal experiments were approved by the Institutional Animal Care and Use
Committees of the University of Arkansas, Fayetteville. A cohort of male C57BL/6J mice were
purchased from Jackson Laboratories. The animals were housed in a temperature-controlled
room and maintained on a 12:12 h light-dark cycle. The mice were given ad libitum access to
normal rodent chow and water.
In the present study, we utilized two different pre-clinical models of muscle atrophy—
hindlimb suspension to recapitulate disuse-induced atrophy and Lewis Lung Carcinoma (LLC)
implantation to induce cancer cachexia. A cohort of control animals was age matched to both
experimental groups. All animals were singly housed to match housing requirements of hindlimb
suspension.
Lewis lung carcinoma culture and implantation
Tumorigenic cells were prepared as previously described (10). Lewis lung carcinoma
cells (ATCC CRL-1642) were plated at passage 2. Cells were cultured in 250 mL culture flasks
in DMEM supplemented with 10% fetal bovine serum supplemented with 1% penicillin and
streptomycin. Once cells reached confluency, they were trypsinized, counted, and diluted in PBS
for implantation. Mice were anesthetized with isoflurane and hair was removed from the right
hind flank. LLC cells (1x106) suspended in 100µL sterile PBS were injected subcutaneously into
the hind flank of a single cohort of mice at 8 weeks of age as previously described. Tumors
developed for approximately 3 weeks. Experimental endpoints were adjusted for excessive tumor
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burden. Animals were anesthetized under isoflurane and body weight was recorded. Plantaris,
gastrocnemius, soleus, extensor digitorum longus (EDL), tibialis anterior, quadriceps, spleen,
epididymal fat, testes, and plasma were quickly collected post-euthanasia. Tissue samples were
weighed and snap-frozen in liquid nitrogen for further processing and stored at -80ºC.
Hindlimb Suspension
Skeletal muscle disuse atrophy was induced by hindlimb suspension as previously
described (39, 68). Mice were subjected to 7 days of hindlimb suspension. Mice were acclimated
to handling by researchers for one week prior to unloading. Unanesthetized animals’ tails were
cleansed with alcohol and betadine, covered with a small amount of benzoin tincture, and dried
until the benzoin became tacky. A hair dryer was used to expedite the drying process. A strip of
traction tape was wrapped around the base of the tail, just above the hairline. Tape was adjusted
so that it did not impede blood circulation and provided an attachment site for the fish-line
swivel device connected to the top of the cage. Mice were attached to a hindlimb suspension
apparatus designed to allow access to all areas of the cage with only their forelimbs able to
contact the cage floor. The unloading device used in our laboratory consists of a single rod that
reaches across the cage. The rod has two rubber stoppers to restrain the mouse from moving too
close to the cage walls and loading its hindlimbs. The fish-line swivel connects to a pulley
system on the rod, allowing the mouse to move with minimal resistance along the rod between
the rubber stoppers. The mouse is suspended at an angle of approximately 30 degrees so that the
front legs are in contact with the cage floor and the hindlimbs are completely unloaded and
unable to reach the floor. The floor is fitted with gridwire to prevent the animal from reloading
its hindlimbs with piled up bedding.
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A small amount of bedding was placed under the gridwire of each cage to absorb urine
and waste. Animals were suspended for seven days and bedding materials were not replaced
during the experiment.
Animals were anesthetized under isoflurane and body mass was recorded. Plantaris,
gastrocnemius, soleus, EDL, tibialis anterior, quadriceps, spleen, epididymal fat, testes, and
plasma was quickly collected post-euthanasia. Tissue samples were weighed and snap-frozen in
liquid nitrogen for further processing and stored at -80ºC.
Proteomics
Sample Collection
Whole blood samples were obtained from animals under isoflurane anesthesia. Samples
were centrifuged at 3.5 g for 15 minutes. Plasma was pipetted into separate sample tubes and
stored at -80ºC. 100 µL plasma was aliquoted and sent to the University of Arkansas Medical
Sciences’ Proteomics Facilities.
Proteomics Analysis
Tandem mass tag (TMT) proteomics was performed off-site (41). Once purified from
plasma samples, proteins were reduced, alkylated, and digested using filter-aided sample
preparation [Nature Methods 6: 359-62 (2009)]. Tryptic peptides were labeled using tandem
mass tag isobaric labeling reagents (Thermo) according to the manufacturer’s instructions and
combined into multiplex same groups. Normalization was achieved by including a pooled
reference sample for each group. Labeled peptide multiplexes were divided into 36 fractions on a
100 x 1.0 mm Acquity BEH C18 column (Waters) using an UltiMate 3000 UHPLC system
(Thermo) with a 40 min gradient from 99:1 to 60:40 buffer A:B ratio. This was done under basic
pH conditions. Samples were then consolidated into 12 super-fractions. The super-fractions were
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further separated by reverse phase XSelect CSH C18 2.5 µm resin (Waters) on an in-line 150 x
0.075 mm column using an UltiMate 3000 RSLCnano system (Thermo). Elution of the peptides
was accomplished using a 60 min gradient from 97:3 to 60:40 buffer A:B ratio. Eluted peptides
were ionized by electrospray (2.15 kV) followed by mass spectrometric analysis on an Orbitrap
Fusion Lumos mass spectrometer (Thermo). MS3 parameters were used for this analysis. MS
data was acquired using the FTMS analyzer in top-speed profile mode at a resolution of 120,000
over a range of 375 to 1500m/z. Upon CID activation with normalized collision energy of 35.0,
MS/MS data was acquired using the ion trap analyzer in centroid mode and normal mass range.
Up to 10 MS/MS precursors were selected for HCD activation with normalized collision energy
of 65.0 using synchronous precursor selection. This was followed by the acquisition of MS3
reporter ion data using the FTMS analyzer in profile mode at a resolution of 50,000 over a range
of 100-500 m/z. Protein identification and reporter ion quantification was accomplished using
MaxQuant (Max Planck Institute) with a parent ion tolerance of 3 ppm, a fragment ion tolerance
of 0.5 Da, and a reporter ion tolerance of 0.01 Da. Scaffold Q+S (Proteome Software) was used
to verify MS/MS based peptide and protein identifications and to perform reporter ion-based
statistical analysis. Protein identifications were accepted if they could be established with less
than 1.0% false discovery and contain at least 2 identified peptides. Protein probabilities were
assigned by the Protein Prophet algorithm [Anal. Chem. 75: 4646-58 (2003)].
Buffer A = 0.1% formic acid, 0.5% acetonitrile
Buffer B = 0.1% formic acid, 99.9% acetonitrile
Both buffers were adjusted to pH 10 with ammonium hydroxide for offline separation.
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Pathway Analysis
Ingenuity Pathway Analysis (IPA; Qiagen, Valencia, CA; http://www.ingenuity.com)
software was used for canonical pathway analysis, upstream analysis, and network discovery.
Immunoblotting
Immunoblotting was performed as we have previously described (10, 28, 37).
Membranes were probed overnight with primary antibodies. Protein targets were selected based
on the proteomic data provided by the UAMS Proteomics Core Facilities: SOD3 (R&D Systems
AF4817) and Saa (R&D Systems AF2948). Primary antibodies were isolated from goat.
Antibodies were diluted in Tris-buffered saline, 0.1% Tween 20 with 5% milk. Membranes were
imaged on Protein Simple FluorChem (Minneapolis, MN). Images were analyzed via Alpha
View software. All bands were normalized to the 25 kDa band of Ponceau S stain used as a
loading control. Plasma was used for immunoblot analysis.
Statistical Analysis
Phenotypic and immunoblot data were analyzed with a one-way ANOVA and Tukey
post-hoc test, α set at 0.05. Proteomic data were analyzed with a one-way ANOVA, α set at 0.05.
Benjamini Hochberg correction adjusted α to 0.026. For proteomic analysis, differentially
expressed proteins (DEP) were identified as surpassing threshold levels of p<0.026 and
Log2FC = 0.6. All statistical analyses were performed with SAS software.
Results
Muscle atrophy induced by cancer cachexia and hindlimb unloading (Table 1.)
Phenotypic descriptors of applicable body and tissue weights are presented in Table 1.
Briefly, when we accounted for tumor mass, total LLC body weight was not significantly
different from control or HU (p>0.05). Total HU body weight was significantly lower (8%) than
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control (p<0.05). In both LLC and HU groups, raw plantaris, gastrocnemius, and quadriceps
weights were significantly lower compared to control (. p<0.05). However, these weights were
not significantly different between atrophic conditions (p>0.05). Soleus weight was lower in HU
compared to control and LLC (33.4% and 23.2%, respectively), while LLC soleus weight was
only significantly lower compared to control (13.2%, p<0.05). Wet spleen weight, a surrogate
marker of inflammation, was ~200% greater in the LLC animals compared to control and HU
(p<0.005). Equivalent tibia lengths across groups suggested no significant differences in body
size.
Global proteomics demonstrates largest differences in LLC-induced cancer cachexia (Table 2.)
Using TMT based discovery proteomics, a total of 369 peptides were identified in the
plasma of the animals in this experiment. Following statistical comparison, 5 peptides were
similarly modulated between LLC and HU groups and were significantly different compared to
CON. Of those, 3 proteins including complement factor 1 (cf1), apolipoprotein B (ApoB), and
coagulation factor IX (F9) were found to be higher in plasma from LLC and HU groups
compared to CON. Conversely, 2 proteins were found to be lower in plasma from LLC and HU
groups compared to CON including complement 7 (C7) and fibulin (Efemp1). However, while
the contents of these proteins were statistically significant, they did not meet the Log2FC
criterion to be considered DE. DE proteins discovered in each analysis are presented in Table 2.
The comparison of LLC and HU plasma did yield 104 DE proteins. Of these, 44 were upregulated and 60 were down-regulated in LLC plasma compared to HU plasma. An evaluation of
LLC and CON plasma resulted in 91 DE proteins—39 up-regulated and 52 down-regulated—in
LLC plasma compared to CON. In the HU and control comparison, 5 up-regulated and 4 downregulated DE proteins were observed; a total of 9 DE proteins.
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Pathway analysis of discovery proteomics (Tables 3-5, Figures 1-4)
Canonical pathway analysis performed by IPA revealed several modulated pathways in
each comparison (Tables 3-5, Figures 1-4). Currently, I am presenting the 5 most modulated
pathways in each comparison. Commonly modulated processes among comparisons include
acute phase response signaling, LXR/RXR activation, and FXR/RXR activation. In the LLC-HU
analysis, these pathways were found to be most modulated in conjunction with atherosclerosis
signaling and NO and ROS production in macrophages. The LLC-control comparison revealed
additional modulations in atherosclerosis signaling and the intrinsic prothrombin activation
pathway. Along with the commonly modulated pathways, the HU-control analysis resulted in
modulations within the coagulation and complement systems. Most of these modulations do not
clearly exhibit activation or inhibition of the pathway. However, IPA was able to predict activity
in some these processes. Acute phase response signaling was up-regulated in LLC plasma
compared to control and HU plasma (z-score: 2.714, 3.051, respectively). LXR/RXR activation
was up-regulated in LLC compared to control and HU plasma (z-score: 0.5, 0.93, respectively).
NO and ROS production in macrophages was down-regulated in LLC plasma compared to HU
(z-score: -1.0), while intrinsic prothrombin activation was up-regulated in the same comparison
(z-score: 0.447).
Many DE proteins implicated in these modulated pathways exhibit predicted activity
across multiple pathways and comparisons. 32 DE proteins, 19 up-regulated and 13 downregulated, were involved in the LLC-HU comparison. 27 DE proteins, 16 up-regulated and 11
down-regulated, were implicated in the LLC-CON comparison. 7 DE proteins, 3 up-regulated
and 4 down-regulated, were found in the HU-control analysis. The protein Serum Amyloid A
(SAA), implicated in acute phase response signaling, LXR/RXR and FXR/RXR activation, were
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involved in every comparison and were the most modulated. Interestingly, SAA responded to
atrophy in a divergent manner, being up-regulated in LLC plasma and down-regulated in HU
plasma (Log2FC: 4.17 LLC, -2.16 HU). Apolipoproteins, Fibrinogens, SerpinA3, SerpinF1,
PON1, antioxidant proteins, and others were found to be predominantly modulated in LLC
plasma. Similarly, SAA, SerpinA1 and Fibrinogens were predominantly modulated in HU
plasma.
Immunoblot confirmation of plasma proteomics
Immunoblot analysis was used to confirm plasma proteomics findings. According to our
proteomics data, SAA was highly expressed in LLC plasma and repressed in HU plasma.
Immunoblot analysis confirmed higher SAA expression in LLC plasma compared to CON.
However, because signals were not present in CON or HU samples, we cannot confirm that SAA
expression in HU plasma was suppressed compared to CON (Figure 5). This blot was not
quantified as SAA signal was only detected in LLC and internal control samples.
Proteomics analysis suggests catalase content was lower in LLC samples compared to
HU plasma. SOD3 was probed as an anti-oxidant surrogate to catalase as the molecular weight of
catalase overlays albumin, thereby making the catalase signal indistinguishable. Immunoblot
analysis did not reveal any significant differences in SOD3 content between LLC plasma and
other conditions (p>0.05). However, mean SOD3 content was lower in LLC plasma compared to
HU and CON (Figure 6).
Discussion
Our study is among the first to compare modulations in plasma proteomes in disuseinduced atrophy and cancer cachexia. Current literature has established that muscle atrophy,
secondary to cancer cachexia or disuse, involves several metabolic processes that shifts the
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muscle towards a catabolic state (11, 60, 62, 69, 72). Additionally, elevated plasma IL-6 levels in
cancer cachexia patients suggest a possible link between the plasma proteome and muscle
wasting (71). Prior observations made by Baltgalvis et al. (6) demonstrated muscle mass was
dependent on IL-6 signaling in cancer cachexia development in the ApcMin/+ mouse model of
colorectal cancer; therefore, circulating factors may be regulating key regulators of muscle mass
in atrophic conditions. In an effort to identify atrokines, differing and similar among etiologies of
muscle atrophy, the present study compared plasma proteomes across disuse-induced atrophy
and LLC-induced cancer cachexia and suggests if muscle mass is a function of circulating
factors, conditions are modulated independently of one another. The proteomic profiles predict
up-regulated acute phase response signaling, LXR/RXR activation, and intrinsic prothrombin
activation and a down-regulation in NO and ROS production in macrophages in LLC plasma.
However, the proteomic profiles predict a down-regulation of acute phase response signaling in
HU plasma. Moreover, LLC plasma possessed approximately 10 times more DE proteins than
HU plasma, further suggesting a greater reliance of cancer cachexia atrophy on the plasma
proteome than under conditions of disuse. Our findings present circulating factors as potential
atrophic modulators, specifically under cachectic conditions. Furthermore, to our knowledge, we
are the first to perform global proteomic analysis in disuse-induced atrophy. The data herein
demonstrate the need for continued investigation of plasma’s role in influencing muscle in
atrophic etiologies.
Modulated pathways observed in atrophic plasma may influence muscle mass
Canonical pathway analysis suggests the involvement of several pathways in muscle
atrophy. In all comparisons, acute phase response signaling, LXR/RXR activation, and
FXR/RXR activation were modulated. LLC plasma exhibited an up-regulation of acute phase
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response signaling LXR/RXR activation and down-regulation of NO and ROS production in
macrophages compared to HU. In addition, intrinsic prothrombin activation was altered in LLC
plasma compared to control, and the coagulation and complement systems were modulated in
HU plasma compared to control. Upstream analyses of these comparisons provided by IPA
identifies key proteins affected by the modulations in atrophic plasma and shed light on potential
plasma-muscle interactions.
Commonly modulated pathways
Acute Phase Response
The acute phase response is associated with a rapid inflammatory response that can be
triggered by many stimuli including neoplastic growth, or tumor development. This response is
associated with fever and an increased concentration of pro-inflammatory cytokines, which is
largely due to changes in hepatic metabolism (Appendix). In particular, the cytokines IL-6,
IL1B, and OSM were predicted to be activated in our analysis, in addition to the STAT3
complex. Several modulated LLC markers observed in our study including down-regulated ALB,
APOA1/2, TTR, RBP4, CAT, and up-regulated fibrinogens, SAA, C4A/C4B. APCS,
SERPINA1, HPX, HP, SERPINF, ITIH3, and ITIH4 are all consistent with this observation. IL6 is a known regulator of muscle mass in some forms of cancer cachexia (6, 70, 71). It has been
suggested to contribute to catabolism by increasing ubiquitin-proteasome activity and reducing
activity of anabolic processes (70). Moreover, in a C26 cachexia model, Bonetto et al. (8) have
observed elevated IL-6/STAT3 transcription in skeletal muscle that was associated with the
expression and secretion of additional acute phase response proteins into the plasma, suggesting
a muscle-plasma interaction and a potential paracrine function of muscle in cachexia. While IL-6
plays a role in cancer cachexia, other modulated proteins identified in this study have exhibited
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atrokine activity as well. SAA, the most modulated protein observed here, has been implicated in
COPD mediated muscle wasting. Passey et al. (42) observed SAA was sufficient to induce
atrophy via pro-inflammatory signaling in the Toll-like receptor 2. In addition, under healthy
conditions, catalase functions as an antioxidant responsible for managing concentrations of
intracellular ROS produced by mitochondria. Selsby et al. (52) observed that overexpression of
catalase in mice with Duchenne’s muscular dystrophy improved muscle function, suggesting
improved antioxidant capacity may ameliorate wasting associated with inflammation and excess
ROS production. It is worth noting that prior work done in our laboratory suggests that
mitochondrial dysfunction precedes wasting in LLC-induced cancer cachexia and in our present
analysis, catalase content is lower in LLC plasma compared to CON. These observations make
SAA and catalase potential therapeutic targets. In addition, our analysis identified the
involvement of various SERPINS. Interestingly, SERPINA3s have been associated with bovine
apoptotic control via caspase inhibition which is important for muscle cell survival and myoblast
differentiation during repair (25). Our analysis revealed that in LLC plasma, some SERPINA3
isoforms are up-regulated while others are down-regulated. This control mechanism presents a
unique opportunity and provides us another potential therapeutic target. In HU, our findings
demonstrated a down-regulation of this acute phase response pathway, suggesting that disuseinduced atrophy is mediated in a different fashion.
LXR/RXR and FXR/RXR Activation
LXR is a hepatic receptor that forms a heterodimer with RXR and is involved in the
regulation of lipid metabolism, inflammation, and cholesterol metabolism. In the up-regulated
state, as observed in LLC plasma, the LXR/RXR pathway increases cholesterol metabolism,
cholesterol biosynthesis, cholesterol transport, lipoprotein synthesis, lipogenesis, and cholesterol
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efflux from hepatocytes (Appendix). In macrophages, up-regulated LXR/RXR is associated with
a proliferated immune response. FXR/RXR is related to the LXR/RXR pathway and serves as a
regulator of bile acid levels. FXR regulates metabolic processes by linking bile acid regulation
with lipoprotein, lipid, and glucose metabolism (Appendix). In our analysis, this regulation of
metabolism coincided with a decrease in apolipoprotein content in LLC plasma. Little is known
about these pathways’ contributions to skeletal muscle mass, but due to overlaps in the DE
protein profiles for acute phase response and atherosclerosis signaling, it is possible that
LXR/RXR and FXR/RXR modulation may influence skeletal muscle in an indirect manner. To
our knowledge, work has yet to be done connecting LXR/RXR and FXR/RXR activity to
cachexia, but their contribution to lipid metabolism make them possible influencers of fat mass, a
loss of which is commonly associated with the cachectic phenotype, also observed here. While
we did see modulations in these pathways in HU plasma, up or down-regulation could not be
predicted, suggesting that links between HU and LLC plasma are lacking in these pathways.
Pathways modulated specifically in LLC
In LLC plasma, atherosclerosis signaling, NO and ROS production in macrophages, and
intrinsic prothrombin activity were modulated. Atherosclerosis signaling was not found to be up
or down-regulated in LLC plasma. Literature suggests that peripheral atherosclerosis can have
negative consequences for muscle (53). These alterations include increased oxidative stress,
increased inflammatory signaling, mitochondrial dysfunction, altered myofiber morphology,
fibrosis, ischemia, and apoptosis (53). Our findings, while not conclusive in determining the
direction of modulation, suggest atherosclerotic signaling has the potential to indirectly
contribute to atrophy.
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NO and ROS production in macrophages was down-regulated in LLC plasma, due to
modulations in proteins such as catalase. The down-regulation of catalase negatively impacts NO
and ROS production in macrophages. This decrease in NO and ROS impairs the macrophage’s
ability to perform standard functions such as responding to infection and neoplasia (65).
Dysfunctional macrophages may indirectly impact muscle mass. In addition to responding to
infection and inflammatory responses, macrophages are needed to debride damaged myofiber
debris and secrete regenerative factors that promote the activation and incorporation of satellite
cells into areas of muscle damage (65). This pathway presents another potential indirect
modulator of cancer cachexia.
Intrinsic prothrombin activity was upregulated in LLC plasma. Deguchi et al. (17)
suggest that myosin can directly influence thrombosis and coagulation of the blood and they
observed higher levels of thrombotic factors in cases of acute trauma. Therefore, it appears that
our finding of up-regulated prothrombin activity does not enhance atrophy, but instead is likely
due to the interaction of inflamed, traumatized muscle and plasma.
Pathways modulated specifically in HU
In HU plasma, we found modulations in acute phase response signaling, LXR/RXR and
FXR/RXR activation, the coagulation system, and the complement system. Of these, only the
acute phase response signaling pathway was predicted to be down-regulated. Other modulations
were deemed neutral. Shifts in the coagulation system were detected. Frigeri et al. (24) also made
this observation and surmised this result to fluid shifts induced by hindlimb unloading.
Therefore, this finding is probably not due to the interaction of plasma and skeletal muscle, but
more likely an artifact of our HU protocol. Similarly, the complement system—an aspect of the
immune system—was found to be modulated in HU plasma. This system is necessary for the
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lysis of foreign cells, clearance of immune complexes, and activation of inflammation and
augmentation of the antibody response. Other studies suggest that immune system sensitivity is
likely reduced in this condition due to stress (24, 27) While coagulation and complement systems
serve vital roles, it is unclear whether there is an interaction between these systems, HU plasma,
and HU muscle that could exacerbate atrophy. Instead it appears these observed modulations are
the result of the stress and fluid shift induced via hindlimb suspension.
Protein modulation in HU
In our analysis, a total 9 DE proteins were detected in HU plasma and of those, 7 were
found to be implicated in highly impacted pathways. This small pool of proteins may represent
potential circulating atrokines associated with disuse-induced atrophy. The most promising of
these targets include Fibrinogen 1 (FN1) and SAA. We observed higher content of FN1 and
lower content of SAA in HU plasma compared to CON. Fibrinogen 1 is a marker commonly
associated with many diseases and Ueki et al. (63) observed that in atrophy induced by burn
injury, elevated fibrinogen was associated with increased inflammation and decreased
mitochondrial quality. When they used a toll-like receptor inhibiting treatment that impaired
fibrinogen’s action, mitochondrial health improved, as did burn injury survival rate.
Interestingly, in disuse-induced atrophy, mitochondrial dysfunction has also been observed.
Increased ROS production, impaired Ca2+ handling, and the release of proteolytic activators all
promote atrophy, making Fibrinogen 1 a potential therapeutic target (46). In LLC plasma, upregulated SAA contributes to atrophy via increasing IL-6 and TNF-α signaling and increasing
induction of Atrogin-1. When exacerbated, IL-6 signaling and Atrogin-1 can have deleterious
effects on muscle mass (42). However, IL-6 and Atrogin-1 are required for healthy muscle
maintenance (40, 73). IL-6 is associated with hypertrophic muscle growth and the regulation of
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energy metabolism and, in the proper concentrations, Atrogin-1 contributes to mitophagy which
allows the mitochondrial network to remove damaged mitochondria and preserve network
quality. In our analysis of HU plasma, SAA is significantly down-regulated, possibly suggesting
that a threshold of SAA expression is required for muscle mass maintenance.
Conclusions and Future Direction
In summary, this is the first study to investigate a comparison of plasma proteomes in
disuse-induced atrophy and cancer cachexia. Several proteins were found to be modulated in
atrophic conditions, though more aberrations to the plasma proteome were detected in cachectic
compared to disuse atrophy. This observation is consistent with a greater reliance of cachexia on
bloodborne signaling as compared to disuse. These DE proteins influenced the activity of many
signaling pathways including acute phase response signaling and LXR/RXR and FXR/RXR
activation. Up-regulated acute phase response signaling in cancer cachexia likely up-regulates
IL-6/STAT3 expression which would cause muscle to secrete additional acute phase proteins,
thereby exacerbating cachexia signals. Interestingly, this finding supports a muscle-plasma
interaction and highlights muscle as a potential paracrine organ in cachexia. A down-regulation
in this same pathway in HU plasma indicates that these etiologies develop independently of each
other. Although future studies are warranted to validate these relationships. To accomplish this,
future experiments should evaluate proteomic profiles in the muscle to verify predicted muscleplasma interactions. This study highlights a clear need for the further study of plasma-muscle
interactions in muscle atrophy.
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Appendix
Table 1. Body and wet tissue weights at time of harvest in control (CON), hindlimb-unloaded
(HU), and Lewis lung carcinoma tumor-bearing mice (LLC). N of 10-14/group was utilized.
Tibia length was used as an estimate of total body size. Tibia length did not differ between
groups; therefore, all tissue weights are presented as non-normalized wet weights. Lettering
denotes statistical significance between groups, alpha set at p<0.05.

Group
Body Weight (g)
Tumor (g)
Body Weight - Tumor (g)
Soleus (mg)
Plantaris (mg)
Gastrocnemius (mg)
EDL (mg)
TA (mg)
Quadriceps (mg)
Spleen (mg)
Gonadal Fat (mg)
Testes (mg)
Tibia (mm)

CON (N=10)
26.06 + 0.47 a
NA
26.06 + 0.47a
10.07 + 0.25 a
21.09 + 0.66 a
131.51 + 1.76 a
10.84 + 0.43
49.41 + 1.0 a
193.71 + 8.58 a
69.05 + 1.89 a
532.16 + 39.94 a
114.91 + 2.98
17.46 + 0.04

LLC (N=14)
26.96 + 0.4 a
1.84 + 0.18
25.12 + 0.43a
8.74 + 0.27 b
16.31 + 0.4 b
119.9 + 2.36 b
9.66 + 0.2
44.15 + 0.89 b
141.31 + 10.15 b
164.52 + 12.07 b
351.03 + 16.27 b
109.82 + 2.64
17.28 + 0.1

HU (N=10)
23.99 + 0.46 b
NA
23.99 + 0.46b
6.71 + 0.25 c
17.17 + 0.48 b
114.03 + 2.23 b
10.48 + 0.48
46.47 + 0.99 a
156.89 + 8.09 b
63.44 + 9.97 a
289.17 + 20.83 b
113.09 + 3.46
17.49 + 0.04

Table 2. Differentially expressed (DE, statistical significance p<0.026, Log2FC > 0.6) proteins
found in each comparison. Number of up-regulated and down-regulated DE proteins shown.

Comparison

Up-Regulated
DE Proteins

LLC-HU
LLC-CON
HU-CON

44
39
5

DownRegulated DE
Proteins
60
52
4

Total DE Proteins
104
91
9
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A)

B)

C)

Figure 1. Percent of modulated molecules in the most affected pathways. A) Modulated molecules in the LLC-HU
comparison. Z-scores for acute phase response: 3.051, LXR/RXR activation: 0.943, NO and ROS production in macrophages:
-1.00. B) Modulated molecules in the LLC-CON comparison. Z-scores for acute phase response: 2.714, LXR/RXR activation:
0.5, intrinsic prothrombin activity: 0.447. C) Modulated molecules in the HU-CON comparison. Z-scores for acute phase
response: -1.0.
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Table 3. DE proteins involved in the 5 most modulated pathways in the LLC-HU comparison.
Acute Phase
Response
Signaling
ALB
AMBP
APCS
APOA1
APOA2
C3
C4A/C4B
FGA
FGB
FGG
FN1
HP
HPX
ITH3
ITH4
RBP4
SAA1
SAA2-4
SERPINA1
SERPINA3
SERPINF1
TTR

LXR/RXR
Activation

FXR/RXR
Activation

Atherosclerosis
Signaling

ALB
AMBP
APOA1
APOA2
APOC2
C3
C4A/C4B
CLU
FASN
FGA
HPX
ITIH4
KNG1
PON1
RBP4
SAA1
SERPINA1
SERPINF1
TTR

ALB
AMBP
APOA1
APOA2
APOC2
C3
C4A/C4B
CLU
FASN
FGA
HPX
ITIH4
KNG1
PON1
RBP4
SAA1
SERPINA1
SERPINF1
TTR

ALB
APOA1
APOA2
APOC2
CLU
COL1A1
COL1A2
ITGB2
PON1
RBP4
SERPINA1

Production of
NO and ROS in
Macrophages
ALB
APOA1
APOA2
APOC2
CAT
CLU
PON1
RBP4
SERPINA1
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Figure 2. DE proteins involved in the 5 most modulated pathways in the LLC-HU comparison. Log2FC for each DE in the LLC-HU
comparison.
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Table 4. DE proteins involved in the 5 most modulated pathways in the LLC-CON comparison.

Acute Phase
Response
Signaling
ALB
AMBP
APCS
APOA1
APOA2
C4A/C4B
FGA
FGB
FGG
FN1
HPX
HPX
ITIH3
ITIH4
RPB4
SAA1
SAA2-4
SERPINA3
SERPINF1
TTR

LXR/RXR
Activation

FXR/RXR
Activation

Atherosclerosis
Signaling

ALB
AMBP
APOA1
APOA2
APOC2
C4A/C4B
CLU
FGA
HPX
ITIH4
KNG1
PON1
RBP4
SAA1
SERPINF1
TTR

ALB
AMBP
APOA1
APOA2
APOC2
C4A/C4B
CLU
FGA
HPX
ITIH4
KNG1
PON1
RBP4
SAA1
SERPINF1
TTR

ALB
APOA1
APOA2
APOC2
CLU
COL1A1
COL1A2
ITGB2
PON1
RBP4

Intrinsic
Prothrombin
Activation
Pathway
COL1A1
COL1A2
FGA
FGB
FGG
KNG1
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Figure 3. DE proteins involved in the 5 most modulated pathways in the LLC-CON comparison. Log2FC for each DE in the LLCCON comparison.
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Table 5. DE proteins involved in the 5 most modulated pathways in the HU-CON comparison.
Acute Phase
Response
Signaling
FN1
ITIH4
SAA1
AMBP
SERPINA1
FGG

LXR/RXR
Activation

FXR/RXR
Activation

Coagulation
System

Complement
System

ITIH4
SAA1
AMBP
SERPINA1

ITIH4
SAA1
AMBP
SERPINA1

SERPINA1
FGG

C7
CFH

HU vs CON
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Figure 4. DE proteins involved in the 5 most modulated pathways in the HU-CON comparison.
Log2FC for each DE in the HU-CON comparison.
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Figure 5. Confirmation immunoblot analysis. A) Representative immunoblot images of SAA
and SOD3. B) Quantification of SOD3 blot normalized to Ponceau S stain.
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Supplemental Figure 1. Acute Phase Response Signaling in nuclei and plasma. Pathway acquired from IPA.
45

Supplemental Figure 2. LXR/RXR activation pathway. Pathway acquired from IPA.
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Supplemental Figure 3. FXR/RXR activation pathway (Wolf et al., 2013).
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